BN
BNGO.US Bionano Genomics Inc
- Market cap
- USD 14.0M
- P/E
- -
- P/B
- 0.46x
- ROE
- -104.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BNGO.US undervalued?
Graham numberThe Graham number of Bionano Genomics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bionano Genomics Inc fundamental analysis
No fundamental analysis for Bionano Genomics Inc yet.
Bionano Genomics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, whi…
Full company profileBionano Genomics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bionano Genomics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.79M | 9.51M | 12.0M | 10.1M | 8.50M | 18.0M | 27.8M | 36.1M | 30.8M | 28.5M | 30.8M |
| Gross Profit | 3.21M | 3.47M | 3.29M | 3.36M | 2.77M | 3.87M | 5.95M | 9.57M | 380K | 6.26M | 15.4M |
| Operating Income | -21.2M | -23.2M | -20.4M | -25.9M | -38.6M | -77.1M | -132M | -215M | -104M | -33.3M | -28.9M |
| EBITDA | -17.3M | -21.3M | -15.8M | -24.7M | -37.1M | -73.9M | -121M | -214M | -97.5M | -16.3M | -23.1M |
| Net Income | -18.8M | -23.4M | -18.5M | -29.8M | -41.1M | -72.4M | -133M | -232M | -112M | -26.4M | -29.6M |
| EPS | -36 | -1,403 | -1,568 | -1,195 | -3.95 | -157 | -275 | -408 | -88 | -4.85 | -2.47 |
| Balance Sheet | |||||||||||
| Total Assets | 14.8M | 10.1M | 24.8M | 30.2M | 60.4M | 377M | 308M | 214M | 76.7M | 73.6M | 46.3M |
| Total Liabilities | 42.0M | 60.4M | 14.7M | 26.6M | 25.4M | 40.0M | 58.1M | 118M | 41.3M | 29.2M | 18.1M |
| Shareholders' Equity | -27.3M | -50.2M | 10.1M | 3.61M | 35.1M | 337M | 249M | 96.2M | 35.4M | 44.4M | 28.2M |
| Cash & Short-term Investments | 5.25M | 1.02M | 16.5M | 17.3M | 38.4M | 251M | 113M | 66.8M | 9.48M | 13.3M | 4.36M |
| Total Debt | 6.63M | 6.73M | 9.03M | 20.1M | 36.4M | 10.7M | 11.7M | 79.4M | 27.3M | 6.92M | 6.54M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -23.5M | -20.8M | -19.9M | -29.5M | -38.3M | -71.9M | -125M | -125M | -68.9M | -16.3M | -19.9M |
| Capital Expenditure | 1.35M | 1.02M | 332K | 61.1K | 4.66M | 1.46M | 3.30M | 1.69M | 103K | 0.00 | 0.00 |
| Free Cash Flow | -24.8M | -21.8M | -20.3M | -29.6M | -38.3M | -73.4M | -128M | -127M | -69.0M | -16.3M | -19.9M |
| Ratios | |||||||||||
| ROE | - | - | -182.5% | -825.6% | -117.3% | -21.5% | -53.2% | -241.8% | -316.7% | -59.4% | -104.8% |
| ROA | -127.5% | -230.3% | -74.6% | -98.8% | -68.0% | -19.2% | -43.1% | -108.4% | -146.1% | -35.9% | -63.9% |
| Net Profit Margin | -277.5% | -245.8% | -154.1% | -294.5% | -483.8% | -402.8% | -476.9% | -643.7% | -364.0% | -92.6% | -95.9% |
| Debt to Equity | - | - | 0.89x | 5.56x | 1.04x | 0.03x | 0.05x | 0.83x | 0.77x | 0.16x | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bionano Genomics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 2.00M | 0.19 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:60 on Jan 27, 2025.
Who owns Bionano Genomics Inc
- Insiders 2.32%
- Institutions 21.10%
- Public & others 76.58%
- Shares outstanding 14.0M
- Free float 11.3M
Top funds holding BNGO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 55.9K | 0.40% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 11.5K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 2.77K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding BNGO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| GSA Capital Partners LLP | 150K | 1.28% | -57.47% | Jun 2026 |
| Carret & Company Inc | 125K | 1.06% | +78.57% | Jun 2026 |
| Geode Capital Management, LLC | 90.0K | 0.76% | -46.28% | Jun 2026 |
| Vanguard Capital Management, LLC | 82.4K | 0.70% | +20.96% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 51.6K | 0.44% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 51.1K | 0.43% | +4.93% | Jun 2026 |
| Jane Street Group LLC | 35.7K | 0.30% | 0.00% | Jun 2026 |
| Prudential Financial Inc | 31.6K | 0.27% | +12.86% | Jun 2026 |
| Northern Trust Corp | 24.6K | 0.21% | +19.70% | Jun 2026 |
| XTX Topco Ltd | 16.3K | 0.14% | 0.00% | Jun 2026 |
| Engineers Gate Manager LP | 12.0K | 0.10% | +1.14% | Jun 2026 |
| HRT FINANCIAL LLC | 11.7K | 0.10% | 0.00% | Jun 2026 |
| BlackRock Inc | 9.94K | 0.08% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 7.81K | 0.07% | +14.80% | Jun 2026 |
| Tower Research Capital LLC | 5.23K | 0.04% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.04K | 0.01% | +11.87% | Jun 2026 |
| Concord Wealth Partners | 1.00K | 0.01% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 957.00 | 0.01% | 0.00% | Jun 2026 |
| UBS Group AG | 812.00 | 0.01% | +4,975.00% | Jun 2026 |
| SBI Securities Co Ltd | 246.00 | 0.00% | +5.13% | Jun 2026 |
Bionano Genomics Inc company profile
- Company name
- Bionano Genomics Inc
- Ticker
- BNGO.US
- Exchange
- USA Stocks
- Listed since
- Aug 21, 2018
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 95
- Fiscal year end
- December
- Address
- 9540 Towne Centre Drive, San Diego, CA, United States, 92121
- Phone
- 858 888 7600
- Website
- bionano.com
About Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Bionano Genomics Inc management
6- Dr. Albert A. Luderer Ph.D.Chairman, Interim CEO, Interim President & Interim Principal Financial Officer · born 1949
- Mr. Mark OldakowskiChief Operating Officer · born 1974
- Mr. Mark Adamchak CPAChief Accounting Officer, Principal Accounting Officer & Controller · born 1980
- Dr. Alex Hastie Ph.D.Chief Scientific Officer
- Mr. Jonathan Dixon J.D.Chief Legal Officer & Corporate Secretary · born 1975
- Mr. Cory KreeckChief People Officer